A randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects

A randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects

Abstract Fingolimod is an oral agent approved for the treatment of relapsing forms of multiple sclerosis (MS), which has demonstrated efficacy in Phase III trials in patients with relapsing-remitting MS (RRMS). The present study was designed to assess bioequivalence between a fingolimod Test capsule...

Full description

Bibliographic Details
Main Authors: Mario Tanguay, Thomas Fröhlich, Mathieu Drouin, Gerald Beuerle
Format: Article
Language:English
Published: SpringerOpen 2018-03-01
Series:AAPS Open
Subjects:
Fingolimod
Bioequivalence
Pharmacokinetics
Multiple sclerosis
Online Access:http://link.springer.com/article/10.1186/s41120-018-0023-3

Internet

http://link.springer.com/article/10.1186/s41120-018-0023-3

Similar Items